{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:13:06Z","timestamp":1758931986495,"version":"3.44.0"},"reference-count":12,"publisher":"BMJ","issue":"2","funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2018,10,24]]},"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>We compared the in vitro antimicrobial activities of tedizolid and linezolid on the Sensititre broth microdilution system for Gram-positive cocci isolates (n=146) from skin and skin structure infections and bloodstream infections, bronchoalveolar lavage and sputum. These pathogens included 40 methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic>, 38 coagulase-negative staphylococci, 20 <jats:italic>Enterococcus faecalis<\/jats:italic> and 48 beta-haemolytic <jats:italic>Streptococcus<\/jats:italic> spp. Susceptibility was simultaneously determined for 48 vanA vancomycin-resistant enterococci isolates 2013\u20132016 from rectal swabs (23 <jats:italic>E. faecalis<\/jats:italic> and 25 <jats:italic>E. faecium<\/jats:italic>, of which 4 were linezolid-non-susceptible). MIC<jats:sub>90s<\/jats:sub> for tedizolid were fourfold to eightfold lower than linezolid on the Sensititre and ranged from 0.12 to 0.5\u2009\u00b5g\/mL for the different pathogen groups. All isolates were susceptible to tedizolid except two vanA <jats:italic>E. faecium<\/jats:italic> strains (MICs of 1 and 2 \u00b5g\/mL, respectively). Categorical and essential agreement for tedizolid were 99.48% and 92%, respectively, between Liofilchem gradient diffusion and Sensititre methods. Overall, the drug exhibited excellent activity against the surveyed Gram-positive pathogens.<\/jats:p>","DOI":"10.1136\/jclinpath-2018-205473","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T12:33:57Z","timestamp":1542371637000},"page":"181-184","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of <i>in vitro<\/i> susceptibility of Gram-positive pathogens from a tertiary care hospital in Singapore to a novel oxazolidinone, tedizolid, by a gradient diffusion method and broth microdilution"],"prefix":"10.1136","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0234","authenticated-orcid":false,"given":"Saugata","family":"Choudhury","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee Kar","family":"Mun","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esme Ng Chu","family":"Xuan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee Shin","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Vasoo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subodha Samanthini","family":"Wickramasinghe","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long Jen","family":"Mee","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"2025092612085540000_72.2.181.1","unstructured":"M Co . Sivextro (tedizolid phosphate) for injection, for intravenous use; Sivextro (tedizolid phosphate) tablet, for oral use. Whitehouse Station: NJ, 2015."},{"key":"2025092612085540000_72.2.181.2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0352-7"},{"key":"2025092612085540000_72.2.181.3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00228-09"},{"key":"2025092612085540000_72.2.181.4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00859-08"},{"key":"2025092612085540000_72.2.181.5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit618"},{"key":"2025092612085540000_72.2.181.6","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1337"},{"key":"2025092612085540000_72.2.181.7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00076-10"},{"key":"2025092612085540000_72.2.181.8","unstructured":"Wayne PA . Performance standards for antimicrobial susceptibility testing: 26th informational supplement. Clinical and Laboratory Standards Institute, 2016: M100\u2013S26."},{"key":"2025092612085540000_72.2.181.9","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02769-14"},{"key":"2025092612085540000_72.2.181.10","unstructured":"EUCAST . Breakpoint tables for interpretation of MICs and zone diameters, version 8.0, 2018."},{"key":"2025092612085540000_72.2.181.11","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00757-06"},{"key":"2025092612085540000_72.2.181.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12941-014-0046-0","article-title":"Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone","volume":"13","author":"Zurenko","year":"2014","journal-title":"Ann Clin Microbiol Antimicrob"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2018-205473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T19:09:04Z","timestamp":1758913744000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2018-205473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,1,22]]},"published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1136\/jclinpath-2018-205473"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2018-205473","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"type":"print","value":"0021-9746"},{"type":"electronic","value":"1472-4146"}],"subject":[],"published":{"date-parts":[[2018,11,16]]}}}